Encysive launches Thelin in Belgium and Luxembourg

Thelin (sitaxentan sodium) is indicated for improving exercise capacity in pulmonary arterial hypertension (PAH) patients classified as World Health Organization (WHO) functional class III. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease (CTD).

Thierry Plouvier, vice president, Europe operations, for Encysive (UK), said: “With the availability of Thelin to physicians and patients in Belgium and Luxembourg, our European commercialization strategy continues to move forward. Thelin adds an additional therapeutic option for treating patients with pulmonary arterial hypertension in the EU.”